News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx Determines Not to Proceed with Public Offering of Common Stock
MOUNTAIN VIEW, Calif. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (the "Company" or "ChemoCentryx") (Nasdaq:CCXI) announced today that it will not conclude an offering of shares of its common stock as announced on Wednesday, September 26, 2018 .
View HTML
Toggle Summary ChemoCentryx Announces Proposed Public Offering of Common Stock
MOUNTAIN VIEW, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of $75 million of its common stock.  In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to
View HTML
Toggle Summary ChemoCentryx to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
MOUNTAIN VIEW, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Tuesday October 2, 2018 at 1:40 p.m. ET .
View HTML
Toggle Summary ChemoCentryx to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in September: 20 th Annual Rodman & Renshaw Global Investment
View HTML
Toggle Summary ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights
-- Completed patient enrollment in Phase III ADVOCATE trial of avacopan in ANCA-associated vasculitis -- -- Ongoing clinical trials with avacopan in C3 Glomerulopathy (C3G) and CCX140 in Focal Segmental Glomerulosclerosis (FSGS), diseases with no approved therapies -- -- Launch of clinical
View HTML
Toggle Summary ChemoCentryx to Hold Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018
MOUNTAIN VIEW, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's second quarter 2018 financial results will be released after market close on Thursday, August 9, 2018 . ChemoCentryx executive management will host a conference call and
View HTML
Toggle Summary ChemoCentryx to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , May 30, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June: Jefferies 2018 Global Healthcare Conference Corporate
View HTML
Toggle Summary ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress
MOUNTAIN VIEW, Calif. , May 23, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced two upcoming presentations during the 55th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress , being held in collaboration with the Danish Society
View HTML
Toggle Summary ChemoCentryx Reports First Quarter 2018 Financial Results and Recent Highlights
-- Patient enrollment in Phase III ADVOCATE trial of avacopan in the treatment of ANCA-associated vasculitis exceeds 85%; Conditional Marketing Authorization (CMA) application under review with European Medicines Agency (EMA) -- -- Ongoing clinical trials with avacopan in C3 Glomerulopathy (C3G)
View HTML
Toggle Summary ChemoCentryx to Hold First Quarter 2018 Financial Results Conference Call on Wednesday, May 9, 2018
MOUNTAIN VIEW, Calif. , May 02, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that the Company's first quarter 2018 financial results will be released after market close on Wednesday, May 9, 2018 . ChemoCentryx executive management will host a conference call and
View HTML